Haemonetics stock consolidates below recent highs despite new hemostasis software launch

Traders Union
All News
Companies
Haemonetics down 0.90% at $77.50 today

Highlights

HAE maintains a bullish technical profile, trading above all major moving averages and supported by upward trend signals.
Momentum indicators diverge, as overbought readings and declining price action increase risk of a near-term pullback or consolidation.
HAE is forecast to consolidate between $75.00 and $82.00 next week, with $75.00 providing critical support and $78.10–$78.30 as pivotal resistance.

Multi-timeframe bullish bias as price holds above key averages

HAE is trading above its MA-20 ($67.86), MA-50 ($62.10), and MA-200 ($63.40), reinforcing a bullish structure across short-, medium- and long-term horizons. The Ichimoku Kijun on D1 is at $66.60, which acts as immediate support since it is below the current price of $77.50. Near-term support levels are identified at MA-20 ($67.86) and Ichimoku Kijun ($66.60), with key support at MA-50 ($62.10). Near-term resistance sits at MA-5 ($78.09), and key resistance clusters at MA-200 ($63.40) are too far below to be currently relevant, so next actionable resistance lies at recent session highs.

Mixed momentum signals as overbought readings contrast with trend support

Momentum signals are mixed, with MACD on D1 bullish and ADX at 27.38 supporting a trending move higher. However, RSI on D1 is elevated at 75.73 and CCI is in overbought territory (130.65), which, together with Stoch RSI signaling strong sell and BBP showing overbought conditions, suggests buyers may be losing control in the short term. The Awesome Oscillator on D1 supports the prevailing bullish trend, but oscillators and momentum indicators are diverging here. HAE has fallen $0.70 (0.95%) over the past week, trading at $77.50 down from $78.20 a week ago. The price is positioned in the lower part of the weekly range, with weekly volatility standing at 9.32%. The week showed a retracement from recent highs, with a steady decline visible after failing to sustain levels above $81.99.

Balanced risk outlook as indicators split and rangebound trade likely

For the coming week, HAE is expected to trade between $75.00 and $82.00, contained within a realistic ±8% band from the current price, and comfortably above its 52-week low ($47.32) but below the yearly high ($87.32). The probability of a price increase is moderate (50%), as only two out of four W1 indicators (RSI-W1 and MA-50-W1) are bullish, while ADX-W1 and MACD-W1 stay neutral. The probability of a move lower is thus equally likely. In the baseline scenario, HAE consolidates within this $75.00–$82.00 range. The bullish scenario would see a breakout above $78.10–$78.30 resistance, with momentum buyers pushing toward $82.00. In the bearish case, a breakdown below $75.00 support could trigger further profit-taking toward the next supports in the $67.86–$66.60 zone.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Earlier, analysts noted that Haemonetics was exhibiting robust bullish momentum, supported by favorable technical trends and strong market positioning. The current analysis signals a shift, with heightened volatility and overbought conditions now prompting investors to watch for a potential consolidation phase or an emerging reversal risk in the near term.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.